Quince Therapeutics, Inc. (QNCX)
(Real Time Quote from BATS)
$0.75 USD
-0.04 (-4.88%)
Updated Oct 7, 2024 01:04 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Quince Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 35 | 52 | 90 | 79 | 39 |
Income After Depreciation & Amortization | -35 | -52 | -90 | -79 | -39 |
Non-Operating Income | 3 | 0 | 0 | 2 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -32 | -52 | -90 | -77 | -37 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -31 | -52 | -90 | -77 | -37 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -31 | -52 | -90 | -77 | -37 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -30 | -51 | -89 | -78 | -40 |
Depreciation & Amortization (Cash Flow) | 4 | 1 | 1 | 1 | -1 |
Income After Depreciation & Amortization | -35 | -52 | -90 | -79 | -39 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 37.24 | 33.50 | 29.72 | 29.18 | 19.06 |
Diluted EPS Before Non-Recurring Items | -0.84 | -1.54 | -3.03 | -2.63 | -1.94 |
Diluted Net EPS (GAAP) | -0.84 | -1.54 | -3.03 | -2.63 | -1.94 |
Fiscal Year end for Quince Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 28.20 | 11.22 | 8.40 | 6.09 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -28.20 | -11.22 | -8.40 | -6.09 |
Non-Operating Income | NA | 0.50 | 0.10 | 1.14 | 0.74 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -27.69 | -11.12 | -8.84 | -5.35 |
Income Taxes | NA | 0.04 | 0.03 | 0.05 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -27.73 | -11.15 | -8.89 | -5.35 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -27.73 | -11.15 | -8.89 | -5.35 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 43.10 | 42.69 | 42.35 | 36.07 |
Diluted EPS Before Non-Recurring Items | NA | -0.18 | -0.26 | -0.21 | -0.15 |
Diluted Net EPS (GAAP) | NA | -0.64 | -0.26 | -0.21 | -0.15 |